1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
182.94 USD   -2.09%
04:18pNovavax sinks after halving sales forecast on low vaccine demand, supply glut
RE
03:57pBioNTech, Pfizer could deliver Omicron-adapted COVID-19 vaccines in October
AQ
09:04aINSIDER SELL : Moderna
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster

06/30/2022 | 11:48pm EDT


© MT Newswires 2022
All news about MODERNA, INC.
04:18pNovavax sinks after halving sales forecast on low vaccine demand, supply glut
RE
03:57pBioNTech, Pfizer could deliver Omicron-adapted COVID-19 vaccines in October
AQ
09:04aINSIDER SELL : Moderna
MT
07:02aINSIDER SELL : Moderna
MT
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/05PUMP / DUMP #40 : This week's gainers and losers
MS
08/05U.S. administers over 7,300 Novavax vaccine doses - CDC
RE
08/04Goldman Sachs Raises Moderna's Price Target to $296 From $290, Maintains Buy Rating
MT
08/04Morgan Stanley Adjusts Moderna's Price Target to $197 From $199, Maintains Equalweight ..
MT
08/04SVB Securities Adjusts Moderna's Price Target to $74 from $77, Keeps Underperform Ratin..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 875 M - -
Net income 2022 11 063 M - -
Net cash 2022 17 049 M - -
P/E ratio 2022 6,88x
Yield 2022 -
Capitalization 71 566 M 71 566 M -
EV / Sales 2022 2,49x
EV / Sales 2023 5,01x
Nbr of Employees 2 700
Free-Float 90,4%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 182,94 $
Average target price 214,00 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235
CELLTRION, INC.2.78%20 815